See the event website https://www.pegsummiteurope.com/immunotherapy

Do not miss our presentations:

- ICT01: A First-in-Class Clinical Stage Anti-BTN3A Antibody with the Capacity to Harness the Vg9/Vd2 T Cellsin Cancer
 Presenter: Loui Madakamutil, PhD, CSO, ImCheck Therapeutics

PROGRESS WITH GAMMA DELTA THERAPY Session, 3 November 07:55 AM

- Mobilizing Gamma-Delta T Cells for Next-Generation Anti-Cancer Immunotherapy–ICT01, an Anti-BTN3AMonoclonal Antibody, Plus IL-2 Triggers Selective g9d2 T Cell Expansion and Activation, While Blunting the IL-2-mediated Increase in Tregs in Non-Human Primates
 Presenter: Aude De Gassart, PhD, Director, Preclinical Research, Imcheck Therapeutics

 ADVANCING NK AND GAMMADELTA CELLS Session, 4 November, 03/20 PM